A new gymnomitrane-type sesquiterpenoid, gymnomitrane-3α,5α,9β,15-tetrol (1), was isolated from the fruiting body of Ganoderma lucidum. Its structure was elucidated using spectroscopic methods. This compound significantly inhibited the growth of epidermal growth factor receptor-tyrosine kinase inhibitor EGFR-TKI-resistant human lung cancer A549 and human prostate cancer PC3 cell lines.
Ganoderma lucidum (Leyss. ex Fr.) Karst is one of the most highly regarded medicinal mushrooms in the world and has been used as a health-preserving and therapeutic agent [1] . To date, over 240 secondary compounds have been isolated from G. lucidum. Lanostane triterpenoids are the major constituents and play a critical role in the biological effects of this mushroom [2, 3] . In addition, meroterpenoids, sesquiterpenoids, steroids, benzofuran, and polysaccharides are also isolated from G. lucidum [4] [5] [6] [7] . In the present study, a water-soluble fraction from the methanol extract of G. lucidum fruiting bodies showed significant cytotoxicity against the EGFR-TKI-resistant human lung cancer cell line A549 and the human prostate cancer cell line PC3. A phytochemical investigation of this water-soluble fraction led to the isolation of a gymnomitrane-type sesquiterpenoid (1).
Compound 1 was obtained as a white solid and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) revealed the ion peak at m/z 269.1744 [M -H]corresponding to the molecular formula C 15 H 26 O 4 . The presence of hydroxyl group in the structure could be proposed from the IR absorption band of 1 at 3420 cm -1 . The 1 H-NMR spectrum of 1 showed three methyl singlets at δ H 0.99 (3H, br s, H-14), 1.15 (3H, br s, H-13) and 1.28 (3H, br s, H-12). A doublet of doublets at δ H 3.57 was attributed to H-5. The 13 C-NMR and DEPT spectra of 1 indicated the presence of 15 signals including 3 CH 3 , 5 CH 2 , 3 CH and 4 C atoms suggesting the sesquiterpene skeleton for 1. Three unsaturation degrees according to the mass spectral data indicated that 1 was a tricyclic structure. The HMBC correlations ( Figure 1 ) showed the coupling from H-14 (δ H 0.99) to C-1 (δ C 40.3), C-5 (δ C 77.9), C-6 (δ C 48.4), C-7 (δ C 54.0) and C-13 (δ C 24.7). These data resembled antrodin F (or gymnomitr-3-ene-9,15-diol) [8] and ganosinensine (or 9,15dihydroxygymnomitr-3-en-5-one) [9] . The difference was that a methylene, an oxygenated methine and an oxygenated quaternary carbon signal were obtained from 1 instead of the double bond and the ketone signals in those two compounds. Thus, 1 was identified as gymnomitrane-3,5,9,15-tetrol. The relative configuration of 1 was determined using the NOESY experiment. A NOESY cross peak between H-12β and H-13β indicated that two 5-member rings were in the cis-fused conformation, which was consistent with the common gymnomitrane structure [8] [9] [10] . The NOE cross-peaks between H-13/H-14, H-1/H-13, H-1/H-12 and H-2/H-12 suggested the β-orientation of 14-CH 3 and H-2. The NOESY correlations of H-1/H-5 and H-1/H-15 established the α-orientation of 3-OH and 5-OH groups [11] . The NOESY cross-peaks of H-9/H-8α, H-9/H-10α, H-13/H-8β and H-12/H-10β indicated the β-orientation of 9-OH. From these data, compound 1 was elucidated to be gymnomitrane-3α,5α,9β,15-tetrol. Due to the low amount, the absolute configuration of 1 remains undetermined by the present data. It is noted that gymnomitrane sesquiterpenes are mainly found in the liverwort [10] and only ganosinensine has been identified in Ganoderma sinense [9] . In the present study, the new gymnomitrane-3α,5α,9β,15-tetrol was isolated from G. lucidum. The cytotoxicity of the isolated compound was investigated on the EGFR-TKI-resistant human lung cancer cell line A549 and the human prostate cancer cell line PC3. Compound 1 inhibited the growth of A549 and PC3 cells by 18.8% and 52.5%, respectively, at a concentration of 30 μM. The inhibition rate increased to 41.9% and 70.0%, respectively, at 100 μM. EGFR-TKI resistance in nonsmall cell lung cancer has become a major clinical problem and currently there is no standard treatment for patients resistant to EGFR-TKI [12] . In this study, gymnomitrane-3α,5α,9β,15-tetrol showed significant cytotoxicity against EGFR-TKI-resistant A549 cells. 
Extraction and isolation:
The air-dried and powdered materials (850 g) were extracted with methanol (2 L × 3 times) in a sonic bath for 30 min. The combined extracts were concentrated under a vacuum to obtain a crude residue (40 g), which was then resuspended in water (0.5 L), and successively extracted by n-hexane and ethyl acetate (each 0.5 L × 3 times). The organic layers were concentrated to give 3.3 g and 17.5 g of n-hexane and ethyl acetate residues, respectively. The water layer was passed through a diaion HP-20 column and eluted by 0%, 50%, and 100% methanol in water. The 100% methanol eluate was chromatographed on a silica gel column eluted by a gradient of 1-100% methanol in dichloromethane to afford six fractions, F1-6. Compound 1 (1.6 mg) was purified from F5 by repeated silica gel column chromatography. Cytotoxicity: The cytotoxic assay was performed using the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. The cells were seeded in 96-well plates at a concentration of 2  10 5 cells/well and treated with various concentrations of test compounds and incubated in a humidified 5% CO 2 atmosphere at 37 ºC. After 72 h incubation, 20 μL of 5 mg/mL MTT was added to each well and incubated for another 4 h. After removing the supernatant, formazan crystals were dissolved in isopropanol and the OD values were measured at 570 nm using a microplate reader. The antitumor agent etoposide was used as a positive control (IC 50 57.8 (A549) and 36.5 (PC3) µM).
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